{"gao_id": "GAO-21-409T", "published": "2021-03-04T12:00:00Z", "released": "2021-03-03T07:00:00Z", "summary": "We have long-standing concerns about the Food and Drug Administration's ability to oversee the increasingly global pharmaceutical supply chain, an issue on our High Risk List since 2009. This testimony discusses some of those concerns and FDA's inspection activities during the COVID-19 pandemic. FDA: Has paused most inspections since March 2020 to safeguard its employees Used alternative inspection tools to oversee drug manufacturing quality, such...", "title": "Drug Safety: FDA's Future Inspection Plans Need to Address Issues Presented by COVID-19 Backlog", "topics": ["Public health emergencies", "Drug approvals", "Drug safety", "pandemics", "Foreign drug inspection", "Supply chain management", "Health Care", "Foreign drug manufacturing", "Compliance oversight", "Drugs", "Prescription drugs"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-21-409t", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-21-409t-highlights.pdf"}, {"title": "Full Report (22 pages)", "url": "https://www.gao.gov/assets/gao-21-409t.pdf"}, {"title": "Accessible PDF (26 pages)", "url": "https://www.gao.gov/assets/720/712959.pdf"}]}